From Research at med.fsu.edu Wed Oct 7 18:00:12 2020 From: Research at med.fsu.edu (Med Research) Date: Wed, 7 Oct 2020 22:00:12 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A176631E@FSUCOM128.med.ad.fsu.edu> Toffler Scholar Program Open to FSU researchers. The Toffler Scholar Program was created by the Trustees of the Karen Toffler Charitable Trust, a 501 C3 nonprofit foundation focused on early-stage research that advances the medical field in profound, high-impact ways. Tapping into the deep legacy of their founders, best-selling authors and futurists, Alvin and Heidi Toffler, the trust exists to be a catalyst for future ? focused breakthroughs. The Toffler Scholar Program focuses on helping university medical researchers gain access to support, and a network for often underfunded innovations. It is a nimble source of financial support for medical researchers working on early-stage, future-focused brain science. Together with the FSU College of Medicine, the program helps foster new ways of thinking and problem solving to find solutions to humanity?s most difficult problems. Toffler Scholar grants are one-year grants that currently range from $20,000 - $30,000 per award. Due November 9, 2020. Med-RA draft review is not required. Fundacion MAPFRE?s Ignacio H. de Larramendi Research Grants: Health Promotion Open to researchers worldwide, the Fundacion MAPFRE is awarding Research Grants totaling 240,000 Euros to provide financial support for undertaking one-year research projects in areas of Health Promotion. The research projects will focus on Health Promotion: * Strategies for habit change: prevention of obesity and promotion of physical activity. * Patient education. * Physical injury assessment. * Health management: clinical quality and safety. Special attention will be given to the projects which, while taking into account the previous topic lines, incorporate aspects related to COVID-19 such as: reducing infections, self-care and the culture of self-protection, relationship between previous health status (lifestyle) and morbimortality, COVID-19 and mental health, etc. Due October 30, 2020. Med-RA deadline to receive draft documents: October 19. NSF Division of Materials Research ? Topical Materials Research Programs: Biomaterials (BMAT), Condensed Matter Physics (CMP), Metals and Metallic Nanostructures (MMN), Polymers (POL) (DMR-TMRP BMAT, CMP, MMN, POL) Research supported by the Division of Materials Research (DMR) focuses on advancing fundamental understanding of materials, materials discovery, design, synthesis, characterization, properties, and materials-related phenomena. DMR awards enable understanding of the electronic, atomic, and molecular structures, mechanisms, and processes that govern nanoscale to macroscale morphology and properties; manipulation and control of these properties; discovery of emerging phenomena of matter and materials; and creation of novel design, synthesis, and processing strategies that lead to new materials with unique characteristics. These discoveries and advancements transcend traditional scientific and engineering disciplines. The Division supports research and education activities in the United States through funding of individual investigators, teams, centers, facilities, and instrumentation. Projects supported by DMR are essential for the development of future technologies and industries that meet societal needs, as well preparation of the next generation of materials researchers. The Biomaterials program supports fundamental materials research related to 1) biological materials, 2) biomimetic, bioinspired, and bioenabled materials, 3) synthetic materials intended for applications in contact with biological systems, and 4) the processes through which nature produces biological materials. Projects are typically interdisciplinary and may encompass scales from the nanoscopic to the bulk. They may involve characterization, design, preparation, and modification; studies of structure-property relationships and interfacial behavior; and combinations of experiment, theory, and/or simulation. Proposals involving biomaterials realized through synthetic biology; fueled biomaterials; stimuli-responsive biomaterials; antimicrobial or antiviral biomaterials; biodegradable, renewable, and sustainable materials; and plant- or fungal- based biomaterials are also encouraged. The emphasis is on novel materials design and development, and discovery of new phenomena. Projects involving in vitro demonstration of biological compatibility and efficacy are appropriate, but the program can support only limited in vivo studies. Tissue engineering and drug/gene delivery projects must have a specific focus on fundamental materials development and characterization. Due November 2, 2020 and November 1, 2021. Med-RA deadline to receive draft documents for 2020 due date: October 20. NSF Division of Integrative Organismal Systems Core Programs The Division of Integrative Organismal Systems (IOS) Core Programs support research aimed at understanding why organisms are structured the way they are and function as they do. Proposals are welcomed in all of the core scientific program areas supported by the Division of Integrative Organismal Systems (IOS). Areas of inquiry include, but are not limited to, developmental biology and the evolution of developmental processes, nervous system development, structure, modification, function, and evolution; biomechanics and functional morphology, physiological processes, symbioses and microbial interactions, interactions of organisms with biotic and abiotic environments, plant and animal genomics, and animal behavior. Proposals should focus on organisms as a fundamental unit of biological organization. Principal Investigators are encouraged to apply systems approaches that will lead to conceptual and theoretical insights and predictions about emergent organismal properties. The clusters/programs in IOS which are participating in submissions to this solicitation are: * Behavioral Systems Cluster: The Behavioral Systems cluster contains the Animal Behavior Program. * Developmental Systems Cluster: Programs within the Developmental Systems Cluster are: the Plant, Fungal and Microbial Developmental Mechanisms Program, the Animal Developmental Mechanisms Program and the Evolution of Developmental Mechanisms Program. * Neural Systems Cluster: Programs within the Neural Systems Cluster are the Organization Program, the Activation Program and the Modulation Program. * Physiological and Structural Systems Cluster: Programs within the Physiological and Structural Systems Cluster are: the Symbiosis, Infection, and Immunity (SII) Program (formerly Symbiosis, Defense and Self-recognition), the Physiological Mechanisms and Biomechanics Program (PMB), the Integrative Ecological Physiology Program (IEP) and the NSF-NIFA Plant Biotic Interactions Program (PBI). * The Plant Genome Research Program: The Plant Genome Research Program (PGRP) supports genome-scale research and tool development to address challenging questions of biological, societal, and economic importance. Proposals intended for PGRP should be submitted directly through its solicitation which can be found on the PGRP program web page along with additional guidelines and current program contacts. Applications welcome anytime. Med-RA deadline to receive draft documents: Ten business days before submission. Health Services Research on Minority Health and Health Disparities (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority health and/or the reduction of health disparities at the health care system-level as well as within clinical settings. Due November 27, 2020; March 17, 2021; November 17, 2021; March 17, 2022; November 17 2022; and February 17, 2023. Note: November 27 is an FSU holiday; applications to this competition must be submitted by November 24. Med-RA deadline to receive draft documents for November 2020 due date: November 12. DKMS Foundation: John Hansen Research Grant?Study of Hematopoietic Stem Cell Transplantation and Cell Therapies in Hematologic Malignancies DKMS, the world?s largest bone marrow donor center, invites young researchers to apply for one of the four scholarships awarded by the DKMS Foundation for Giving Life through its John Hansen Research Grant program. Each of the four recipients of a Hansen grant will receive approximately $270,000 over a period of three years. The research should be in the field of stem cell therapy and have the goal of sustainably and effectively supporting and advancing the fight against blood cancer. Various aspects may be covered, including but not restricted to transplant immunology, stem cell donation, cell manufacturing, as well as diagnostic and therapeutic strategies. Applicants must have a doctoral degree that was awarded within the past eight years. Due December 8, 2020. Med-RA deadline to receive draft documents: November 23 (due to Thanksgiving holiday). Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional) Through this Funding Opportunity Announcement, the National Cancer Institute intends to advance our understanding of: the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and the risk factors for infection. Such studies should inform and advance efforts to reduce or eliminate KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of HIV infection. Due December 15, 2020 and December 14, 2021. Med-RA deadline to receive draft documents for December 2020 due date: December 2. Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple comorbidities associated with HIV infection. Due January 7, 2021; May 7, 2021; January 7, 2022; May 7, 2022; and January 7, 2023. Med-RA deadline to receive draft documents for January 2021 due date: December 14 (due to Winter Break). Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain (R21 / R01 Clinical Trial Not Allowed) R21 R01 These Funding Opportunity Announcements invite research grant applications studying mechanisms of HIV-1 persistence in myeloid cells and strategies to target this reservoir in the central nervous system. Basic and translational research in domestic and international settings are of interest. Due January 8, 2021. Med-RA deadline to receive draft documents: December 14 (due to Winter Break). Using Syndemics to Understand HLBS Disease Emergence and Progression in People with HIV (PWH)(R01 Clinical Trial Not Allowed) This funding opportunity announcement is intended to support research project grant (R01) applications that propose to utilize a syndemics (synergistic epidemic) framework to elucidate the role of social, economic, environmental, behavioral, structural, psychological factors in promoting the synergistic interactions and clustering of heart, lung, blood, and sleep (HLBS) comorbidities among people with HIV at the population level. The ultimate goal is to identify strategies that foster holistic approaches in the clinical management of people living with HIV who have HLBS comorbidities, and to utilize existing data to assess the feasibility and cost-effectiveness of such approaches. Due January 11, 2021 and December 14, 2021. Med-RA deadline to receive draft documents for January 2021 due date: December 15 (due to Winter Break). Cohort Studies To Improve Our Understanding of Influenza Immunity, Vaccine Response and Effectiveness in Older Adults (65 years and older) (U01 Clinical Trial Not Allowed) This initiative will support the use of longitudinal cohorts to develop greater understanding of important elements of influenza immunity that impact vaccine response and vaccine effectiveness in older adults (those 65 and older). In addition, this work will increase our understanding of how these elements relate to severe outcomes from influenza virus infection in older adults (i.e., hospitalization and death). Due February 4, 2021. Med-RA deadline to receive draft documents: January 25. Drug Development Collaboratory (UG3 / UH3 Clinical Trial Required) The purpose of this Funding Opportunity Announcement is to support intramural-extramural collaborations on late-stage translational science projects between NCATS Therapeutic Development Branch (TDB) and extramural researchers, for therapeutic development of small molecules, biologics, or gene therapies. The UG3 phase will provide support for late stage pre-clinical work and clinical trial planning that is conducted at applicant institutions. The goal of any collaboration with TDB is to enable an IND application by the end of the UG3 phase. If UG3 milestones are met and an IND is cleared, support may be provided for an early stage clinical trials in the UH3 phase that will be conducted at the applicant institutions. Due February 9, 2021; June 9, 2021; February 9, 2022; June 9, 2022; February 9, 2023; and June 9, 2023. Med-RA deadline to receive draft documents for February 2021 due date: January 27. Understanding Evolutionary Dynamics of Influenza to Inform and Improve Vaccine Strain Selection (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to support research to improve understanding of the evolutionary dynamics of seasonal influenza to increase our capacity to predict the emergence of new antigenic variants and more accurately select strains for use in the seasonal influenza vaccine. Due February 11, 2021. Med-RA deadline to receive draft documents: February 1. Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed) To support research to better define the role of the granuloma, the hallmark structure of pulmonary tuberculosis (TB), in TB disease and disease outcomes. Improved understanding of the granuloma will provide a much-needed knowledge base for the development of improved therapeutic approaches. Due February 22, 2021. Med-RA deadline to receive draft documents: February 9. Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01) The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, serum, and genomic DNA) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This opportunity allows investigators to apply for access to the biospecimens from the PATH Study. Information about the PATH Study and this resource may be found on the PATH Study series page at the University of Michigan?s National Addiction & HIV Data Archive Program website, part of the Inter-University Consortium for Political and Social Research?s website. Due April 30, 2021; October 29, 2021; April 29, 2022; October 31, 2022; April 28, 2023; and October 31, 2023. Med-RA deadline to receive draft documents for April 2021 due date: April 19. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Fri Oct 16 09:45:29 2020 From: Research at med.fsu.edu (Med Research) Date: Fri, 16 Oct 2020 13:45:29 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A176A62D@FSUCOM128.med.ad.fsu.edu> BrightFocus Foundation Alzheimer's Disease Research The goal of the program is to accelerate our understanding of the biological mechanisms underlying Alzheimer?s Disease and related dementias as well as innovative approaches to better diagnose, prevent or delay the progress of the disease. Preference is made for exciting pilot projects that would not, at their present stage, be competitive for large government or industry awards. Typically, these awards are made to early stage investigators, or to more established investigators who are proposing particularly innovative research. Grants of up to $300,000 over three years will be awarded. Due November 10, 2020. Med-RA deadline to receive draft documents: October 28. Templeton World Charity Foundation: Grand Challenges for Human Flourishing Templeton World Charity Foundation has launched a new strategy to support new scientific research on human flourishing and to translate related discoveries into practical tools. Over the next five years, the Foundation will support a range of projects across three distinct stages: discovery, development, and launch. We hope that this commitment will lead to the development of innovative solutions and the launch of new practices that make a lasting impact on human flourishing. Before picking a focal point for the discovery stage of this five-year strategy, we plan to gather new ideas through an open-submission process. To achieve this, we?ve issued this Request For Ideas (RFI) to gather input as broadly as possible. We invite researchers across disciplines to participate in an initial phase of idea generation and development. Ideas selected will be used by the Foundation to shape its priorities for scientific discovery. Applicants whose ideas are chosen through the RFI process may be eligible to apply for one of the grant opportunities based on the idea; to serve as an advisor to Templeton World Charity Foundation as it supports funding in the area; to serve as a champion/talent scout to find other people in the area whom the foundation can support; and to have their idea published in a sponsored edition of a top journal or foundation media outlet. We seek bold ideas and rigorous experiments that use new conceptual frameworks to move past age-old debates and lead to significant breakthroughs. We expect to invest approximately $40,000,000 through the Grand Challenges for Human Flourishing. Priority will go to interdisciplinary scientific research on humanity?s cognitive, affective, social, and spiritual well-being. We are particularly interested in capacities that can be enhanced to promote human flourishing. We are also committed to the use of open science practices, such as the preregistration of hypotheses, replication studies, and data sharing. Ideas due November 11, 2020. Med-RA deadline to receive draft documents: October 28. Alpha-1 Foundation: Research in Alpha-1 Antitrypsin Deficiency Alpha-1 Antitrypsin (AAT) Deficiency is a genetic condition that may result in serious lung disease in adults and/or liver disease at any age. The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and improving the lives of those affected worldwide. To advance this mission, the foundation is inviting LOIs for its research grants program. Through the program, grants of up to $100,000 per year for up to two years will be awarded in support of research that contributes to the understanding of the basic biology of AAT expression and the pathogenesis/management of AAT Deficiency. Consideration also will be given to projects that provide insight into the development of information that may contribute to new therapies for AAT Deficiency. Letter of intent due November 13, 2020. Med-RA deadline to receive draft documents: November 2. NSF: Law & Science (LS) The Law & Science Program considers proposals that address social scientific studies of law and law-like systems of rules, as well as studies of how science and technology are applied in legal contexts. The Program is inherently interdisciplinary and multi-methodological. Successful proposals describe research that advances scientific theory and understanding of the connections between human behavior and law, legal institutions, or legal processes; or the interactions of law and basic sciences, including biology, computer and information sciences, STEM education, engineering, geosciences, and math and physical sciences. Scientific studies of law often approach law as dynamic, interacting with multiple arenas, and with the participation of multiple actors. Fields of study include many disciplines, and often address problems including, though not limited, to: * Crime, Violence, and Policing * Cyberspace * Economic Issues * Environmental Science * Evidentiary Issues * Forensic Science * Governance and Courts * Human Rights and Comparative Law * Information Technology * Legal and Ethical Issues related to Science * Legal Decision Making * Legal Mobilization and Conceptions of Justice * Litigation and the Legal Profession * Punishment and Corrections * Regulation and Facilitation of Biotechnology (e.g., Gene Editing, Gene Testing, Synthetic Biology) and Other Emerging Sciences and Technologies * Use of Science in the Legal Processes Due January 15, 2021 and August 2, 2021. Med-RA deadline to receive draft documents for January 2021 due date: January 4. New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3 / UH3 Clinical Trial Not Allowed) Through this Funding Opportunity Announcement (FOA), the National Cancer Institute and National Institute of Environmental Health Sciences invite applications to support innovative scientific research in new prospective cohorts that addresses knowledge gaps in cancer etiology and carcinogenesis processes with a focus on environmental exposures. Applicants are encouraged to use validated and reproducible innovative techniques to measure environmental exposures relevant to the proposed scientific research questions. The cohorts should include racial/ethnic minorities and understudied populations to address the unequal burden of cancer that currently exists in those populations. In this FOA, environmental exposures refer to physical, chemical, and biological factors external to a person, and related behavioral factors. Due January 29, 2021. Med-RA deadline to receive draft documents: January 19. Utilizing In Vitro Functional Genomics Advances for Gene-Environment (G x E) Discovery and Validation (R01 Clinical Trial Not Allowed) The purpose of this funding opportunity is to solicit applications that fully integrate recent innovative advances of in vitro functional genomics tools/technologies and approaches for environmental health and toxicology research. The overall goal of this NIEHS led initiative is to generate proof-of-principle studies incorporating these new in vitro approaches, together with well characterized exposures, to further our understanding of gene-environment (G x E) interactions in complex human disorders. Due February 1, 2021. Med-RA deadline to receive draft documents: January 19. NSF Growing Convergence Research (GCF) Growing Convergence Research (GCR) at the National Science Foundation was identified as one of 10 Big Ideas. Convergence research is a means for solving vexing research problems, in particular, complex problems focusing on societal needs. It entails integrating knowledge, methods, and expertise from different disciplines and forming novel frameworks to catalyze scientific discovery and innovation. GCR identifies Convergence Research as having two primary characteristics: * Research driven by a specific and compelling problem. Convergence Research is generally inspired by the need to address a specific challenge or opportunity, whether it arises from deep scientific questions or pressing societal needs. * Deep integration across disciplines. As experts from different disciplines pursue common research challenges, their knowledge, theories, methods, data, research communities and languages become increasingly intermingled or integrated. New frameworks, paradigms or even disciplines can form sustained interactions across multiple communities. A distinct characteristic of convergence research, in contrast to other forms of multidisciplinary research, is that from the inception, the convergence paradigm intentionally brings together intellectually diverse researchers and stakeholders to frame the research questions, develop effective ways of communicating across disciplines and sectors, adopt common frameworks for their solution, and, when appropriate, develop a new scientific vocabulary. Research teams practicing convergence aim at developing sustainable relationships that may not only create solutions to the problem that engendered the collaboration, but also develop novel ways of framing related research questions and open new research vistas. This GCR solicitation targets multi-disciplinary team research that crosses directorate or division boundaries and is currently not supported by NSF programs, initiatives and research-focused Big Ideas. Proposers must make a convincing case that the research to be conducted is within NSF?s purview and cannot be supported by existing NSF programs and multidisciplinary initiatives. The proposers should outline a five-year research plan delineated in two phases, Phase I: years 1-2, and Phase II: years 3-5. Successful proposals will be funded initially for two years and then each team?s progress will be evaluated based on a report and presentation that the team will make to a panel of reviewers at NSF. Teams that show significant progress during the first two years will receive funding for an additional three years. Interested researchers may request up to $1,200,000 total for the first two years and $2,400,000 for the last three years. Due February 3, 2020. Med-RA deadline to receive draft documents: January 21. Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 and UH2 / UH3 Clinical Trials Not Allowed) UH3 The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as ?markers? or ?biomarkers?) and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. UH2 / UH3 Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as ?markers? or ?biomarkers?) and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this FOA supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this FOA supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. Investigators responding to this FOA must address both UH2 and UH3 phases. Milestones to be accomplished in the UH2 phase for transition to the UH3 phase must be proposed by the investigators. Due February 18, 2021; July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; and October 10, 2023. Med-RA deadline to receive draft documents for February 2021 due date: February 8. NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) solicits grant applications for the preparation of book-length manuscripts and other works of academic and/or public health policy value to U.S. health professionals, public health officials, biomedical researchers and historians of the health sciences. Due February 26, 2021; February 24, 2022; and February 24, 2023. Med-RA deadline to receive draft documents for February 2021 due date: February 15. NSF Division of Molecular and Cellular Biosciences: Investigator-Initiated Research Projects (MCB) The Division of Molecular and Cellular Biosciences (MCB) supports quantitative, mechanistic, predictive, and theory-driven fundamental research designed to promote understanding of complex living systems at the molecular, subcellular, and cellular levels. While recognizing the need for thorough and accurate descriptions of biological complexes and pathways, the priority of the Division is to support work that advances the field by capturing the predictive power of mechanistic, quantitative, and evolutionary approaches. Proposals are solicited to support research relevant to the four MCB core clusters: * Cellular Dynamics and Function * Genetic Mechanisms * Molecular Biophysics * Systems and Synthetic Biology MCB gives high priority to research projects that use theory, methods, and technologies from life and physical sciences, mathematics, computational sciences, and engineering to address major biological questions that elucidate the rules governing subcellular and cellular processes. Research supported by MCB uses a range of experimental and computational approaches?including in vivo, in vitro and in silico strategies?and a broad spectrum of model and non-model organisms, including microbes and plants. Typical research supported by MCB integrates theory and experimentation. Projects are particularly welcome that address the emerging areas of: multi-scale integration; transformative methods and resources (when driven by compelling biological questions); molecular and cellular evolution; the synthesis of life-like systems; and the quantitative prediction of the phenome from genomic information. Highest funding priority is given to applications that have outstanding intellectual merit and strong broader impacts, while proposals with weaknesses in either category (or those that are perceived as likely to have an incremental impact) will not be competitive. Proposals that are motivated by relevance to human health and disease treatment are not appropriate for the Division and will be returned without review. Applications accepted anytime. Med-RA deadline to receive draft documents: Ten business days before submission to the sponsor. NSF: Transitions to Excellence in Molecular and Cellular Biosciences Research (Transitions) The Division of Molecular and Cellular Biosciences (MCB) has developed a new opportunity to enable researchers with a strong track record of prior accomplishment to pursue a new avenue of research or inquiry. This funding mechanism is designed to facilitate and promote a PI?s ability to effectively adopt empowering technologies that might not be readily accessible in the PI?s current research environment or collaboration network. Transformative research likely spans disciplines and minimizing the practical barriers to doing so will strengthen research programs poised to make significant contributions. The award is intended to allow mid-career or later-stage researchers (Associate or Full Professor, or equivalent) to expand or make a transition in their research programs via a sabbatical leave or similar mechanism of professional development and then develop that research program in their own lab. This award will also enable the PI to acquire new scientific or technical expertise, facilitate the investigator?s competitiveness, and potentially lead to transformational impacts in molecular and cellular bioscience. The award would fund up to six months of PI salary during the first sabbatical or professional development year, followed by support for continued research for two subsequent years upon the PI?s return to normal academic duties. Requests for flexibility in the timing of the sabbatical or professional development year will be considered with appropriate justification. Please contact the cognizant program director for the solicitation. Through this solicitation MCB and NSF hope to develop a novel mechanism that will encourage investigators to expand and/or transition to new research areas aligned with MCB priorities, to increase retention of investigators in science, and to ensure a diverse scientific workforce that remains engaged in active research. Proposals that are motivated to understand the molecular and cellular basis of disease and disease treatments are not appropriate for the Division and will be returned without review. Proposals addressing major open questions at the intersections of biology with other disciplines, such as physics, chemistry, mathematics, computer sciences, and engineering are of particular interest to the program. Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days before submission to the sponsor. Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia (U01 Clinical Trial Optional) INIA provides a foundation for addressing emerging NIAAA research priorities. Technologies exploring spatial and temporal resolution of brain function measures are currently being advanced by the NIH Brain Research Through Advancing Innovative Neurotechnologies [BRAIN] initiative and methods to measure behavior from previously inaccessible sources and with greater temporal resolution are emerging. Artificial intelligence tools and methods are also emerging which will expand analytical capabilities in alcohol research. These new technologies and paradigms provide opportunities for researchers to investigate the diversity of alcohol use disorder (AUD) among affected individuals and generate new therapeutic targets. The INIA initiative is an avenue for applying emerging neuroscience research capabilities derived from BRAIN and other sources toward understanding the neurobiology of AUD. This FOA invites research that will contribute to advancing integrative research efforts on novel mechanism-focused hypotheses pertaining to the development and remediation of excessive drinking associated with AUD. Potential themes could include current research gaps such as negative affect (e.g., anxiety, hyperkatifeia, emotional pain, dysphoria) and cognitive control dysfunction (e.g., impulse control) contributing to addiction. In addition, we encourage research addressing hypotheses exploring interactions between alcohol and other relevant causal influences on the development of AUD pathology such as trauma, pain conditions, and social isolation. In addition to complying with NIH?s Sex as a Biological Variable policy, investigators are encouraged to examine mechanisms underlying sex differences in AUD related measures. Further, capitalizing on technological advances from BRAIN and from other sources in examining brain microcircuitry, functional interactions between neurons and surrounding specific cell types and structure, and microbiome influences on brain function represent additional research considerations for understanding excessive alcohol drinking. Due May 26, 2021. Med-RA deadline to receive draft documents: May 13. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Thu Oct 29 11:38:11 2020 From: Research at med.fsu.edu (Med Research) Date: Thu, 29 Oct 2020 15:38:11 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A176F25C@FSUCOM128.med.ad.fsu.edu> Marsha Rivkin Center for Ovarian Cancer: Research Grants * Pilot Study Program Two-year awards of total $75,000. Pilot Study Program awards will support investigator-initiated projects in all areas of ovarian cancer research. In addition, projects designed to analyze data from already funded clinical trials will be considered. Funds are for direct costs only. Due December 1, 2020. Med-RA deadline to receive draft documents: November 16 (due to Fall Break). * Scientific Scholar Award Two-year grants at $120,000 each, Scientific Scholar Awards are intended to assist promising laboratory and clinical scientists in pursuing a career as an independent investigator in ovarian cancer research. Funds are for direct costs only. Due December 1, 2020. Med-RA deadline to receive draft documents: November 16 (due to Fall Break). * Bridge Funding Award The Rivkin Center provides interim funding of up to $30,000 for six months to researchers who have submitted to the National Institutes of Health (NIH) or an original proposal to the Department of Defense (DoD) pertaining to ovarian cancer and who were not funded but received a score close to the funding threshold. With more data, ovarian cancer researchers stand a better chance of being successfully funded with a stronger, resubmitted proposal. Due May 1, 2021. Med-RA deadline to receive draft documents: April 20. NSF: Integrative Strategies for Understanding Neural and Cognitive Systems (NCS) The complexities of brain and behavior pose fundamental questions in many areas of science and engineering, drawing intense interest across a broad spectrum of disciplinary perspectives while eluding explanation by any one of them. Rapid advances within and across disciplines are leading to an increasingly interwoven fabric of theories, models, empirical methods and findings, and educational approaches, opening new opportunities to understand complex aspects of neural and cognitive systems through integrative multidisciplinary approaches. This program calls for innovative, convergent, boundary-crossing proposals that can best capture those opportunities and map out new research frontiers. NSF seeks proposals that pursue high-value scientific and technical risks by transcending the perspectives and approaches typical of disciplinary research efforts. This cross-directorate program is one element of NSF?s participation in the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative (https://www.nsf.gov/brain/). The program focuses on four aspects of neural and cognitive systems that are current targets of converging interdisciplinary interests. NCS projects must advance the foundations of one or more of these focus areas, as described further within the solicitation: 1. Neuroengineering and Brain-Inspired Concepts and Designs 2. Individuality and Variation 3. Cognitive and Neural Processes in Realistic, Complex Environments 4. Data-Intensive Neuroscience and Cognitive Science Proposals must address both risk and reward: high-risk, high-payoff approaches are expected. Proposals must also go beyond the scope of any NSF core program, or they will not be considered responsive to this solicitation. NCS will consider two classes of proposals. FOUNDATIONS awards will support high-risk, high-payoff projects that advance the foundations of one or more NCS focus areas. FRONTIERS awards (FY2021 and FY2023 competitions only) will support ambitious, highly integrative, interdisciplinary projects that advance and connect multiple integrative research threads to tackle challenges that would be intractable without a high level of collaboration and coordination. Community-driven efforts such as workshops or synthesis papers are also encouraged, to map out new frontiers at the interface of neuroscience and other disciplines that could reshape brain research and its applications. FRONTIERS: Required letter of intent due December 15, 2020. Proposals due January 15, 2021. Med-RA deadline to receive draft documents for letter of intent: December 2. Med-RA deadline to receive draft documents for proposal: January 4. FOUNDATIONS: Proposals due January 15, 2021. Med-RA deadline to receive draft documents: January 4. Elucidation of mechanisms underlying complex morbidities of SUD and other mental Illnesses in people living with HIV/AIDS (R01 Clinical Trial Optional) The purpose of this funding opportunity is to support research that will elucidate neurobehavioral mechanisms underlying multimorbidities involving SUD and co-occurring psychiatric disorders in people living with HIV. Due January 6, 2021. Med-RA deadline to receive draft documents: December 14 (due to Winter Break). Collaborative Approaches to Engineer Biology for Cancer Applications (U01 Clinical Trial Not Allowed) This funding opportunity announcement invites applications to develop and apply innovative synthetic biology approaches to address challenges across the spectrum of cancer research. Projects will be required to apply a technology, based on an engineered biological system, to an important and well-defined cancer research question. Collaborative transdisciplinary teams are expected, with PIs representing expertise in cancer research, engineering, and other disciplines relevant to synthetic biology. Due January 15, 2021. Med-RA deadline to receive draft documents: January 4. NIDDK Education Program Grants (R25 Clinical Trial Not Allowed) The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation?s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: * Courses for Skills Development: For example, advanced courses in a specific discipline or research area, clinical procedures for research, or specialized research techniques. NIDDK supports skill development for research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases. * Research Experiences: For example, for undergraduate students: to provide hands-on exposure to research, to reinforce their intent to graduate with a science degree, and/or to prepare them for graduate school admissions and/or careers in research; for graduate and medical, dental, nursing and other health professional students: to provide research experiences and related training not available through formal NIH training mechanisms; for postdoctorates, medical residents and faculty: to extend their skills, experiences, and knowledge base in order to engage in research activities. These experiences are expected to be relevant for research within the mission of NIDDK that includes diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases. Due January 28, 2021; January 28, 2022; and January 31, 2023. Med-RA deadline to receive draft documents for January 2021 due date: January 14. NSF: Mid-Career Advancement (MCA) The MCA offers an opportunity for scientists and engineers at the Associate Professor rank (or equivalent) to substantively enhance and advance their research program through synergistic and mutually beneficial partnerships, typically at an institution other than their home institution. Projects that envision new insights on existing problems or identify new but related problems previously inaccessible without new methodology or expertise from other fields are encouraged. Partners from outside the PI?s own sub-discipline or discipline are encouraged, but not required, to enhance interdisciplinary networking and convergence across science and engineering fields. By (re)-investing in mid-career investigators, NSF aims to enable and grow a more diverse scientific workforce (more women, persons with disabilities, and underrepresented minorities) at high academic ranks, who remain engaged and active in cutting-edge research. Participating programs in the Directorates for Biological Sciences (BIO), Geosciences (GEO), Engineering (ENG), Social, Behavioral and Economic Sciences (SBE), and Education and Human Resources (EHR) will accept MCA proposals. Due February 1, 2021 and February 7, 2022. Med-RA deadline to receive draft documents for 2021 due date: January 19. NSF Human Networks and Data Science The Human Networks and Data Science program (HNDS) supports research that enhances understanding of human behavior and how humans interact with and are influenced by their environments by leveraging data science and network science research across a broad range of topics. HNDS research will identify ways in which dynamic, distributed, and heterogeneous data can provide novel answers to fundamental questions about individual and group behavior. HNDS is especially interested in proposals that provide data-rich insights about human networks to support improved health, prosperity, and security. HNDS has two tracks: 1. Human Networks and Data Science ? Infrastructure (HNDS-I). Infrastructure proposals will address the development of data resources and relevant analytic techniques that support fundamental Social, Behavioral and Economic (SBE) research. Successful proposals will, within the financial resources provided by the award, construct user-friendly large-scale next-generation data resources and relevant analytic techniques and produce a finished product that will enable new types of data-intensive research. The databases or techniques should have significant impacts, either across multiple fields or within broad disciplinary areas, by enabling new types of data-intensive research in the SBE sciences. 2. Human Networks and Data Science ? Core Research (HNDS-R). Core research proposals will address theoretically motivated questions about the nature, causes, and/or consequences of human behavior (broadly defined) that occurs within contexts defined by the networks that determine the human experience, from the biological networks in the human body to the sociocultural, economic and geospatial networks that comprise human societies. HNDS-R proposals should be submitted through any primary disciplinary program within SBE and not to this solicitation. HNDS-R is interested in leveraging multi-scale, multi-level network data and techniques of network analysis to further theory development across the social sciences. Proposals that address human behavior within complex hierarchical network structures and/or that address problems involving nonlinear dynamics and network heterogeneity are particularly encouraged. Supported projects are expected to yield results that will enhance, expand, and transform theory and methods, and that generate novel understandings of human networks ? particularly understandings that can improve the outcomes of significant societal opportunities and challenges. HNDS-R encourages core research proposals that make innovative use of NSF-supported data networks, data bases, centers, and other forms of scientific infrastructure including those developed by HNDS-I (formerly RIDIR) projects. Due February 4, 2021 and February 2, 2022. Med-RA deadline to receive draft documents for 2021 due date: January 25. BRAIN Initiative Cell Census Network (BICCN) Scalable Technologies and Tools for Brain Cell Census (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) intends to accelerate the use of scalable technologies and tools to enhance brain cell census research, including the development of technology platforms and/or resources and the generation of spatiotemporal cell census data and/or resources. Applications are expected to address limitations and gaps of existing technologies/tools as a benchmark against which the improvements or competitive advantages of the proposed ones will be measured. The improvements include throughput, sensitivity, selectivity, scalability, spatiotemporal resolution and reproducibility in cell atlas analyses. The projects funded under this FOA will align with the overarching goals of the BRAIN Initiative Cell Census Network (BICCN) and are expected to enable the generation of a large amount of cell census data using the proposed technologies or via collaboration with the BICCN. Due March 10, 2021. Med-RA deadline to receive draft documents: February 25. New Technologies for the In vivo Delivery of Gene Therapeutics for an HIV Cure (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to support research on the development and validation of innovative strategies to deliver anti-HIV gene therapies efficiently to specific target cells in vivo. Due March 17, 2021; March 17, 2022; and March 17, 2023. Med-RA deadline to receive draft documents for 2021 due date: March 4. Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 / R01 Clinical Trial Not Allowed) R21 R01 These Funding Opportunity Announcement (FOAs) solicit applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects (parent projects). The parent projects can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The parent project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to these FOAs will undergo an accelerated review and award process. The objective of these FOAs is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community?s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease. Due March 18, 2021; July 20, 2021; November 18, 2021; March 18, 2022; July 20, 2022; and November 18, 2022. Med-RA deadline to receive draft documents for March 2021 due date: March 8. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: